Home › Compare › ABBV vs PFE

ABBV vs PFE — Head-to-Head 2026

AbbVie vs Pfizer: OVR ratings, revenue growth, valuation, and volatility compared.

ABBV — Replaced Humira successfully. 4% yield with growing coverage. OVR: 83 (A-Tier).

PFE — COVID windfall gone. Pipeline must deliver. OVR: 64 (C-Tier).

HEAD-TO-HEAD

METRICABBV — AbbViePFE — Pfizer
OVR Rating8364
TierA-TierC-Tier
Momentum Score55/10028/100
Stability Score85/10070/100
Value Score72/10078/100
Revenue Growth+4%-41%
P/E Ratio16x14x
Beta0.650.55
Market Cap$330B$150B
Dividend Yield4.0%6.1%
S&P 500YesYes

FREQUENTLY ASKED QUESTIONS

Which is stronger, ABBV or PFE?
MarketMVP rates ABBV at 83 OVR (A-Tier) and PFE at 64 OVR (C-Tier). ABBV scores higher.
Is ABBV more volatile than PFE?
ABBV beta: 0.65. PFE beta: 0.55. ABBV is more volatile.
Which has higher revenue growth?
ABBV: +4%. PFE: -41%. ABBV is growing faster.
EXPLORE BOTH ON MARKETMVP →
ABBV Full Analysis PFE Full Analysis All Comparisons

Educational purposes only. MarketMVP OVR scores and ratings are educational tools — not financial advice or recommendations. Always do your own research. Full disclaimer